Company intelligence / Profile preview

Granite Club

Basel, Basel-Stadt, Switzerlandgraniteclub.com ↗

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Granite Bio is a clinical-stage immunology biotech developing first-in-class monoclonal antibodies targeting fundamental drivers of inflammation, autoimmunity, and fibrosis. Its lead asset GRT-001 depletes pro-inflammatory monocytes and is in Phase 1a trials with plans for a Phase 1b trial in inflammatory bowel disease. The second asset GRT-002 targets interleukin-3 and is expected to enter clinical trials in 2026

Therapeutic areas: GastroenterologyRare DiseasesImmunology
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

Versant Ventures’ Ridgeline Discovery EngineUniversity of Regensburg labs of Prof. Matthias MackInvestors include Novartis Venture Fund, Forbion, Sanofi Ventures

Beyond the preview

Go deeper on Granite Club.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Granite Club.

Explore the full profile